ADBiotech Co., Ltd. (KOSDAQ:179530)
South Korea
· Delayed Price · Currency is KRW 3,105.00
-55.00 (-1.74%)
Last updated: Jun 25, 2025
ADBiotech Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Net Income | -4,075 | -7,952 | -2,863 | 2,696 | -2,664 | -7,345 |
| Depreciation & Amortization | 1,023 | 1,025 | 1,134 | 725.66 | 651.6 | 181.09 |
| Loss (Gain) From Sale of Assets | 4.43 | 4.43 | - | - | -1.82 | -2.27 |
| Asset Writedown & Restructuring Costs | 421.96 | 421.96 | 2,590 | 45.21 | - | - |
| Loss (Gain) From Sale of Investments | 352.05 | 4,263 | -3,023 | -390.47 | 24.16 | 5,876 |
| Stock-Based Compensation | 93.44 | 97.85 | 80.28 | 172.9 | 74.91 | 116.51 |
| Provision & Write-off of Bad Debts | 205.66 | 156.41 | -389.33 | 391.19 | 418.3 | 80.25 |
| Other Operating Activities | -776.37 | -990.26 | -1,523 | -7,354 | 790.4 | 576.24 |
| Change in Accounts Receivable | -1,883 | -1,338 | 660.74 | 1,197 | -2,135 | -441.5 |
| Change in Inventory | 456.67 | -183.68 | 450.38 | -1,071 | -232.37 | 102.07 |
| Change in Accounts Payable | 1,165 | 1,390 | -129.32 | -730.49 | 631.69 | -18.83 |
| Change in Unearned Revenue | - | - | -49.75 | - | - | - |
| Change in Other Net Operating Assets | -1,076 | -986.07 | 3,378 | -4,274 | 257.49 | -143.46 |
| Operating Cash Flow | -4,088 | -4,092 | 314.93 | -8,592 | -2,186 | -1,019 |
| Capital Expenditures | -201.74 | -193.38 | -239.9 | -726.72 | -3,561 | -5,289 |
| Sale of Property, Plant & Equipment | 10.23 | 10.23 | - | - | 1.82 | 2.27 |
| Cash Acquisitions | - | - | -1,381 | - | - | - |
| Sale (Purchase) of Intangibles | - | - | -50 | - | - | - |
| Investment in Securities | -3,188 | 1,322 | 4,094 | -1,106 | -1,198 | 486.69 |
| Other Investing Activities | 43.17 | 102.61 | -15.86 | 34.09 | 256.9 | 217.21 |
| Investing Cash Flow | -3,336 | 1,241 | 2,407 | -2,199 | -4,500 | -4,583 |
| Short-Term Debt Issued | - | 1,100 | 1,560 | 2,057 | 1,000 | 1,757 |
| Long-Term Debt Issued | - | 5,500 | 900 | - | 4,500 | 4,940 |
| Total Debt Issued | 7,600 | 6,600 | 2,460 | 2,057 | 5,500 | 6,697 |
| Long-Term Debt Repaid | - | -6,107 | -3,345 | -793.7 | -252.3 | -3,021 |
| Net Debt Issued (Repaid) | 1,873 | 493.24 | -885.19 | 1,263 | 5,248 | 3,676 |
| Issuance of Common Stock | 3,149 | - | - | 9,928 | 198.5 | 68.5 |
| Other Financing Activities | -165.45 | -8.83 | - | -396.88 | -12.77 | -2.12 |
| Financing Cash Flow | 4,856 | 484.41 | -885.19 | 10,794 | 5,433 | 6,742 |
| Foreign Exchange Rate Adjustments | -13.36 | -10.24 | -1.56 | -19.03 | 9.41 | -11.93 |
| Net Cash Flow | -2,582 | -2,376 | 1,836 | -16.18 | -1,243 | 1,128 |
| Free Cash Flow | -4,290 | -4,285 | 75.03 | -9,319 | -5,747 | -6,308 |
| Free Cash Flow Margin | -36.79% | -38.48% | 0.72% | -87.66% | -48.54% | -64.27% |
| Free Cash Flow Per Share | -463.09 | -468.81 | 8.21 | -924.41 | -747.71 | -1262.15 |
| Cash Interest Paid | 539.15 | 355.34 | 333.45 | 158.75 | 137.52 | 105.47 |
| Cash Income Tax Paid | - | -0.92 | 5.51 | 21.24 | -13.28 | 13.34 |
| Levered Free Cash Flow | -5.65 | -363.01 | -1,259 | -3,247 | -4,961 | - |
| Unlevered Free Cash Flow | 517.7 | 63.28 | -992.12 | -3,170 | -4,880 | - |
| Change in Net Working Capital | -1,944 | -1,707 | -1,067 | 226.69 | 1,074 | - |
Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.